Headline
The latest stories from AHA Today.
The Centers for Medicare & Medicaid Services released a substantial number of new waivers related to COVID-19. The waivers apply nationwide and are retroactive to March 1, 2020.
AHA asked the Department of Health and Human Services and Centers for Medicare & Medicaid Services to directly and expediently distribute to rural and urban hospitals and health systems funds from the Public Health and Social Services Emergency Fund that were designated for providers in the…
The Partnership to Amend 42 CFR Part 2, a coalition of nearly 50 health care organizations including the AHA, applauded Congress’ important step to modernize privacy regulations affecting the disclosure of patients’ substance use disorder treatment records.
The Joint Commission has issued a new standards FAQ on monitoring patients at high risk for suicide who have known or suspected COVID-19.
The Food and Drug Administration expanded and updated guidance on the emergency use authorization for personal protective equipment.
Getting health care workers on the front line the personal protective equipment they need is the main focus right now for hospital and health system leaders, AHA President and CEO Rick Pollack said on CNN.
The Centers for Medicare & Medicaid Services announced additional details about its implementation of reporting exceptions and extensions across is quality reporting and value programs.
The Food and Drug Administration Friday authorized emergency use of the ID NOW Instrument in patient care settings to quickly test for COVID-19 through direct nasal or throat swab testing.
The Federal Emergency Management Agency coordinated flights from Asia with 80 tons of personal protective equipment for New York, New Jersey and Connected, with more flights going to Illinois today and Ohio Tuesday, FEMA said today in an update on the federal government’s response to COVID-19.
The Department of Health and Human Services said it will speed the development and manufacturing of vaccines to prevent COVID-19, starting a candidate from Johnson & Johnson subsidiary Janssen Research & Development.